Competition in pharmaceuticals: more product- than price-oriented? Livio GarattiniAnna Padula Editorial 09 October 2017 Pages: 1 - 4
Competition and quality indicators in the health care sector: empirical evidence from the Dutch hospital sector R. R. CroesY. J. F. M. Krabbe-AlkemadeM. C. Mikkers Original Paper Open access 03 January 2017 Pages: 5 - 19
A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK Evelina A. ZimovetzAlain JosephJosephine A. Mauskopf Original Paper Open access 16 January 2017 Pages: 21 - 35
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy Umberto RestelliAlfredo AlbertiDavide Croce Original Paper 22 December 2016 Pages: 37 - 44
Investigating social inequalities in older adults’ dentition and the role of dental service use in 14 European countries Jing ShenStefan Listl Original Paper Open access 07 January 2017 Pages: 45 - 57
Good jobs, good pay, better health? The effects of job quality on health among older European workers Golo Henseke Original Paper Open access 13 January 2017 Pages: 59 - 73
A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations Felix AchanaStavros PetrouOn behalf of Medicines for Neonates Investigators Original Paper Open access 09 February 2017 Pages: 75 - 86
Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial Bernhard MichalowskySteffen FlessaWolfgang Hoffmann Original Paper 03 February 2017 Pages: 87 - 102
A “healthy immigrant effect” or a “sick immigrant effect”? Selection and policies matter Amelie F. ConstantTeresa García-MuñozTzahi Neuman Original Paper 31 January 2017 Pages: 103 - 121
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries Aris AngelisAnsgar LangePanos Kanavos Original Paper Open access 16 March 2017 Pages: 123 - 152
Corruption costs lives: evidence from a cross-country study Qiang LiLian AnMina Baliamoune-Lutz Original Paper 14 February 2017 Pages: 153 - 165
Patient preferences: a Trojan horse for evidence-based medicine? Afschin Gandjour Current Opinion 30 June 2017 Pages: 167 - 172